. Author manuscript; available in PMC: 2012 May 1.

Published in final edited form as: J Pharmacol Toxicol Methods. 2011 Feb 26;63(3):296–303. doi: 10.1016/j.vascn.2011.02.003

Table 4.

Clinical hematology

	Baseline	+3 weeks	+8 weeks	+12 weeks	+16 weeks	Group p-value vs. Control

WBC (×10⁶/L)
Control	5.5 ± 0.6	5.6 ± 0.5	4.8 ± 0.6	5.2 ± 0.7	4.8 ± 0.9
STZ-45	4.1 ± 0.4	4.4 ± 0.4	3.6 ± 0.5	3.5 ± 0.5	3.1 ± 0.3	NS
STZ-55	4.3 ± 0.3	4.8 ± 0.6	3.5 ± 0.4	3.6 ± 0.5	3.5 ± 0.4	NS
RBC (×10¹²/L)
Control	6.9 ± 0.1	6.9 ± 0.1	6.4 ± 0.2	6.5 ± 0.3	6.9 ± 0.2
STZ-45	7.3 ± 0.2	6.9 ± 0.2	6.0 ± 0.3 ^*	6.3 ± 0.3	6.3 ± 0.4	0.88
STZ-55	6.6 ± 0.2 ^#	6.5 ± 0.1	5.5 ± 0.2	5.2 ± 0.3 ^*	5.2 ± 0.3 ^*^†	0.03
Hct (%)
Control	51.9 ± 0.8	52.7 ± 1.0	47.9 ± 2.5	50.5 ± 2.2	49.0 ± 3.1
STZ-45	54.6 ± 1.7	52.8 ± 2.5	46.7 ± 2.3	46.3 ± 2.9	47.1 ± 0.0	0.87
STZ-55	50.1 ± 1.3	47.5 ± 0.8	37.3 ± 1.6 ^*	38.7 ± 2.2 ^†	38.0 ± 1.0 ^*^†	0.01
Hb (g/L)
Control	166 ± 3	171 ± 3	160 ± 9	168 ± 8	167 ± 9
STZ-45	177 ± 5	166 ± 5	154 ± 8	156 ± 10	149 ± 0	0.91
STZ-55	161 ± 4	157 ± 3	126 ± 6	126 ± 7 ^†	127 ± 5 ^*^†	0.007

WBC: white blood cells; RBC: red blood cells;

p<0.05 vs. Baseline;

^†

p<0.05 vs. CTL; NS indicates no significant overall group difference by repeated measures ANOVA